St. Peters Hospital

Type: Teaching hospital
Where: Albany, NY
Medicare CCN: 330057
Received: $212,936 in 191 records, 2020 ($7,732 general, $205,204 research)
Source: CMS Open Payments search ↗

On this site

Nonprofit: ST PETERS HOSPITAL Fuzzy (name and state)

By year

Program year	Kind	Records	Amount
2020	General payment	9	$7,732
2020	Research payment	182	$205,204

By company

Company	Records	Amount	Years
Merck Sharp & Dohme LLC	172	$188,309	2020
Tactile Systems Technology Inc	5	$13,137	2020
Cardiovascular Systems Inc.	5	$3,757	2020
Edwards Lifesciences Corporation	2	$3,328	2020
Gilead Sciences, Inc.	1	$3,000	2020
Stryker Corporation	3	$1,142	2020
Linvatec Corporation	1	$135	2020
Abbott Laboratories	1	$100	2020
Ethicon Inc.	1	$26	2020

By nature of payment

Nature	Records	Amount
Research payment	182	$205,204
Education	2	$3,328
Grant	2	$3,135
Gift	4	$1,168
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	1	$100

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2020-12-31	Edwards Lifesciences Corporation	$1,664	Education	In-kind items and services	ForeSight Elite tissue oximetry system Device, Noninvasive Hemodynamic Monitoring		2020
2020-12-31	Edwards Lifesciences Corporation	$1,664	Education	In-kind items and services	ForeSight Elite tissue oximetry system Device, Noninvasive Hemodynamic Monitoring		2020
2020-12-31	Stryker Corporation	$233	Gift	Cash or cash equivalent	NONE Device, NONE		2020
2020-12-31	Linvatec Corporation	$135	Grant	In-kind items and services	HALL POWER Device, ORTHOPEDIC SURGERY		2020
2020-12-31	Stryker Corporation	$81	Gift	Cash or cash equivalent	NONE Device, NONE		2020
2020-12-29	Merck Sharp & Dohme LLC	$26,055	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$141	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$132	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$132	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$70	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$70	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$62	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$62	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$47	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$29	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$29	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$29	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$29	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$15	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$5	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$3	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$3	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-12-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-30	Tactile Systems Technology Inc	$2,457	Research payment	Cash or cash equivalent	Flexitouch Device, Advanced Pneumatic Compression	A Feasibility Study Evaluating the Impact Flexitouch Plus with Connectivity has on Compliance in Patients with Breast Ca	2020
2020-11-09	Merck Sharp & Dohme LLC	$94	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$88	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$88	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$65	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$47	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$47	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$41	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$41	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-11-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$10	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$5	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$3	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-09	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-11-04	Tactile Systems Technology Inc	$1,576	Research payment	Cash or cash equivalent	Flexitouch Device, Advanced Pneumatic Compression	A Feasibility Study Evaluating the Impact Flexitouch Plus with Connectivity has on Compliance in Patients with Breast Ca	2020
2020-10-29	Cardiovascular Systems Inc.	$186	Research payment	Cash or cash equivalent	Coronary Orbital Atherectomy System Device, Atherectomy Device	ECLIPSE	2020
2020-10-22	Merck Sharp & Dohme LLC	$8,000	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-10-22	Merck Sharp & Dohme LLC	$3,252	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-10-22	Merck Sharp & Dohme LLC	$500	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-10-20	Merck Sharp & Dohme LLC	$9,430	Research payment	Cash or cash equivalent	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-10-15	Merck Sharp & Dohme LLC	$6,388	Research payment	Cash or cash equivalent	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-10-08	Merck Sharp & Dohme LLC	$61	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-10-08	Merck Sharp & Dohme LLC	$41	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-10-08	Merck Sharp & Dohme LLC	$40	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-10-08	Merck Sharp & Dohme LLC	$23	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-10-08	Merck Sharp & Dohme LLC	$22	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-10-08	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-10-08	Merck Sharp & Dohme LLC	$16	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-10-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-10-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-29	Merck Sharp & Dohme LLC	$7,584	Research payment	Cash or cash equivalent	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-29	Tactile Systems Technology Inc	$731	Research payment	Cash or cash equivalent	Flexitouch Device, Advanced Pneumatic Compression	A Feasibility Study Evaluating the Impact Flexitouch Plus with Connectivity has on Compliance in Patients with Breast Ca	2020
2020-09-24	Merck Sharp & Dohme LLC	$3,562	Research payment	Cash or cash equivalent	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-17	Merck Sharp & Dohme LLC	$6,859	Research payment	Cash or cash equivalent	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-11	Tactile Systems Technology Inc	$1,372	Research payment	Cash or cash equivalent	Flexitouch Device, Advanced Pneumatic Compression	A Feasibility Study Evaluating the Impact Flexitouch Plus with Connectivity has on Compliance in Patients with Breast Ca	2020
2020-09-08	Merck Sharp & Dohme LLC	$117	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$117	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$110	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$17	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$15	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$9	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$6	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$4	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-08	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-09-01	Gilead Sciences, Inc.	$3,000	Grant	Cash or cash equivalent			2020
2020-08-31	Stryker Corporation	$827	Gift	In-kind items and services	S3 Device, PATIENT CARE - PC		2020
2020-08-17	Abbott Laboratories	$100	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2020
2020-08-07	Merck Sharp & Dohme LLC	$26,055	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-08-03	Merck Sharp & Dohme LLC	$26,055	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-07-23	Cardiovascular Systems Inc.	$3,420	Research payment	Cash or cash equivalent	Coronary Orbital Atherectomy System Device, Atherectomy Device	ECLIPSE	2020
2020-05-08	Merck Sharp & Dohme LLC	$103	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$103	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$78	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$78	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$72	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$72	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$60	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$60	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$60	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$60	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$58	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$58	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$55	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$55	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$7	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$7	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-05-08	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-04-30	Cardiovascular Systems Inc.	$18	Research payment	Cash or cash equivalent	Coronary Orbital Atherectomy System Device, Atherectomy Device	ECLIPSE	2020
2020-04-28	Merck Sharp & Dohme LLC	$26,055	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-04-20	Merck Sharp & Dohme LLC	$8,180	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj	2020
2020-04-10	Ethicon Inc.	$26	Gift	In-kind items and services			2020
2020-04-02	Cardiovascular Systems Inc.	$112	Research payment	Cash or cash equivalent	Coronary Orbital Atherectomy System Device, Atherectomy Device	ECLIPSE	2020
2020-03-24	Tactile Systems Technology Inc	$7,000	Research payment	Cash or cash equivalent	Flexitouch Device, Advanced Pneumatic Compression	A Feasibility Study Evaluating the Impact Flexitouch Plus with Connectivity has on Compliance in Patients with Breast Ca	2020
2020-03-09	Merck Sharp & Dohme LLC	$424	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$396	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$272	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$141	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$141	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$141	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$124	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$124	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$118	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$99	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$94	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$72	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$72	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$65	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$59	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$59	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$59	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$59	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$59	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$49	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$47	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$40	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$37	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$35	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$34	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$32	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$30	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$23	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$22	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$20	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$17	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$15	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$15	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$12	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$12	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$12	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$10	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$9	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$7	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$3	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$2	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-09	Merck Sharp & Dohme LLC	$0	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-03-05	Cardiovascular Systems Inc.	$18	Research payment	Cash or cash equivalent	Coronary Orbital Atherectomy System Device, Atherectomy Device	ECLIPSE	2020
2020-02-20	Merck Sharp & Dohme LLC	$21,652	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-02-20	Merck Sharp & Dohme LLC	$545	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-02-20	Merck Sharp & Dohme LLC	$409	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with	2020
2020-02-10	Merck Sharp & Dohme LLC	$212	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$205	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$70	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$61	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$47	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$47	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$36	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$27	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$17	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$13	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020
2020-02-10	Merck Sharp & Dohme LLC	$3	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in	2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.